*Reflecting our continued growth and evolution, Asha Therapeutics is now First Atom Therapeutics - Redefining Medicine Atom-by-Atom. For more information please contact us at info@firstatomtx.com
PRISM Platform™: The Next Generation of Drug Development by Design
The PRISM Platform™ is a first in the industry AI-integrated rational drug design technology that leverages atom-by-atom compound design
A complete technology from target ID to specific compound and clinical optimization
Designing new medicines through the power of physics
A differentiated artificial intelligence approach to drug development
Breakthrough technology at every point in the design process
Physics-based target modeling with SD ™
3
- Generates bespoke docking models for each protein binding site for unparalleled accuracy of computational Kd determination
- Focuses on protein dynamics, engaging solvent-corrected conformational search methods and induced fit effects when evaluating binding energetics
Novel Pocket Searching with CrypticPockets™
- Searches the entire protein data bank for similar proteins by pocket similarity
- Model organism target overlay to evalate differences with test models and human binding sites
- Employs structural dynamics simulation to identify novel pockets not resolved by crystal structure or cryo-EM
ADME and Pharmacokinetic optimization using ETCH™
- Unlike currently available prediction platforms, PRISM™ does not utilize any chemo-informatics in its evaluation of safety and ADME/PK properties. Metabolic susceptibility is determined using quantum-based molecular energetics and membrane simulation in addition to binding evaluation against the entire known proteome.
Optimizing Drug Safety using SafetyNet™
- Leverages the power of Target Fingerprinting and AI to predict drug safety
- Correlates unique fingerprint of all FDA approved drugs and clinical safety data to predict potential adverse effects of designed compounds all prior to synthesis, reducing time and risk to clinic
